Background Topical cyclosporine A (also known as ciclosporin A)(CsA) is an anti‐
inflammatory that has been widely used to treat inflammatory ocular surface diseases. Two …

Cequa®, a unique and first-in-class preservative free cyclosporine-A (CsA) nanomicellar
topical formulation was recently approved by US FDA for treatment of dry eye disease or …

Purpose To compare the safety and efficacy of intense pulsed light (IPL) followed by
meibomian gland expression (MGX), against monotherapy of MGX. Methods Patients with …

Introduction: The development of ophthalmic formulations able to deliver hydrophilic and
hydrophobic drugs to the inner structures of the eye and restore the preocular tear film has …

The eye is an isolated and complex organ, with multiple robust anatomical and physiological
barriers on the ocular surface which protect it from noxious insults such as the blink reflex …

Purpose Vernal keratoconjunctivitis (VKC) is a chronic, allergic, and potentially severe
ocular disease affecting children and adolescents that can lead to impaired quality of life …

Dry eye disease (DED) has become common on a global scale in recent years. There is a
wide prevalence of DED in different countries based on various ethnicities and environment …

Introduction Early initiation of anti-inflammatory therapies is recommended for dry eye
disease (DED) to break the vicious cycle of pathophysiology. However, there is limited …

Keratoconjunctivitis sicca, also known as dry eye disease (DED), is a prevalent,
multifactorial disease associated with compromised ocular lubrication, ocular surface …

Purpose: The aim of this study was to assess the long-term safety and efficacy of
perfluorohexyloctane (PFHO) ophthalmic drop (formerly NOV03) for treatment of dry eye …